Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial

BACKGROUND: We evaluated the immunogenicity and safety of a booster dose of NVX-CoV2373 in Japanese adults who had completed a primary series of COVID-19 mRNA vaccine 6–12 months previously. METHODS: This single-arm, open-label, phase 3 study, conducted at two Japanese centres, enrolled healthy adul...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuriyama, Kenji, Murakami, Kyoko, Masuda, Taisei, Sugiura, Kenkichi, Sakui, Sho, Schuring, Ron P., Mori, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165021/
https://www.ncbi.nlm.nih.gov/pubmed/37198021
http://dx.doi.org/10.1016/j.vaccine.2023.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165021/
https://www.ncbi.nlm.nih.gov/pubmed/37198021
http://dx.doi.org/10.1016/j.vaccine.2023.05.001

Ejemplares similares